两种利那洛肽迟释制剂治疗便秘型肠易激综合征患者的随机试验
这项2b期研究将532例便秘型肠易激综合征患者随机分配至安慰剂或7种利那洛肽剂量组(DR1 30/100/300 μg、MD-7246 30/100/300 μg或IR 290 μg),每日一次治疗12周。所有DR1和MD-7246组腹痛较基线和安慰剂均有更大改善;DR1和IR组完全自发排便频率改善数值上更大、APC+1应答率更高,MD-7246组结果与安慰剂相似。
要点
- 利那洛肽DR1和MD-7246所有剂量组腹痛较基线和安慰剂均有更大改善。
- DR1和IR组完全自发排便频率改善数值上更大,APC+1应答率高于安慰剂。
- MD-7246组肠道症状参数结果与安慰剂相似,腹泻发生率也与安慰剂相似。
核心结论
- 改变肠道给药部位可能将利那洛肽的疼痛缓解作用与分泌效应解耦。
- MD-7246各剂量均可见持续、轻度的腹痛改善且对肠道症状参数影响有限,值得进一步研究其作为腹痛新型治疗(不论IBS亚型)。
研究设计与样本
- 2b期随机试验,患者随机接受安慰剂或7种每日一次利那洛肽剂量之一(DR1 30、100、300 μg;MD-7246 30、100、300 μg;IR 290 μg),治疗12周。
- 共随机分配532例患者,平均年龄45.1岁,大多数为女性(83.3%)和白人(64.7%)。
主要发现
- 所有利那洛肽DR1和MD-7246组在整个治疗期间腹痛较基线和安慰剂均有更大改善。
- 利那洛肽DR1和IR组完全自发排便频率较基线改善数值上大于安慰剂,APC+1应答率高于安慰剂。
- MD-7246组结果与安慰剂相似。
- DR1和IR组最常见不良事件为腹泻;MD-7246与安慰剂之间腹泻发生率相似。
关键数值与推荐
- 关键疗效终点为腹痛和完全自发排便频率较基线的变化,以及6/12周联合APC+1应答率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immediate-release (IR) formulation of linaclotide 290 μg improves abdominal pain and constipation (APC) in patients with irritable bowel syndrome (IBS) with constipation. Delayed-release (DR) formulations were developed on the premise that targeting the ileum (delayed-release formulation 1 [DR1]) or ileocecal junction and cecum (MD-7246, formerly DR2) would modulate linaclotide's secretory effects while preserving pain relief effects. METHODS: This phase 2b study randomized patients with IBS with constipation to placebo or 1 of 7 once-daily linaclotide doses (DR1 30, 100, or 300 μg; MD-7246 30, 100, or 300 μg; or IR 290 μg) for 12 weeks. Key efficacy endpoints were change from baseline in abdominal pain and complete spontaneous bowel movement frequency, and 6/12-week combined APC+1 responder rate. RESULTS: Overall, 532 patients were randomized; mean age was 45.1 years, and most were women (83.3%) and White (64.7%). All linaclotide DR1 and MD-7246 groups experienced greater improvements in abdominal pain from baseline and vs placebo throughout treatment. Linaclotide DR1 and IR led to numerically greater improvements from baseline in complete spontaneous bowel movement frequency and higher APC+1 responder rates compared with placebo; MD-7246 results were similar to placebo. Diarrhea was the most common adverse event with DR1 and IR; rates were similar between MD-7246 and placebo. DISCUSSION: Altering the site of drug delivery in the intestine might uncouple linaclotide's pain relief from secretory effects. Persistent, modest abdominal pain improvement with limited impact on bowel symptom parameters, as seen across MD-7246 doses, warrants further study of MD-7246 as a novel treatment for abdominal pain, regardless of IBS subtype.
引用
- Chey WD, Sayuk GS, Bartolini W, et al. Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation. Am J Gastroenterol. 2021. PMID: 33065589. doi:10.14309/ajg.0000000000000967
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。